Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
Addressing Racial and Socioeconomic Disparities in CLL Care
February 13th 2024In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment.
Read More
Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical Cancer
November 15th 2023Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Watch
Niraparib Maintenance Improves Survival in BRCA Wild-Type Ovarian Cancer
August 1st 2023In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.
Read More
Key Takeaways from the OUTBACK Trial of Adjuvant Chemotherapy in Cervical Cancer
July 23rd 2022Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.
Watch
Examining Trends of Biomarker Testing With the MYLUNG Study in mNSCLC
June 23rd 2022During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More